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EXTRA VIEW
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ABSTRACT
ERK5, encoded by MAPK7, has been proposed to play a role in cell proliferation, thus attracting interest as a
cancer therapeutic target. While oncogenic RAS or BRAF cause sustained activation of the MEK1/2-ERK1/2
pathway, ERK5 is directly activated by MEK5. It has been proposed that RAS and RAF proteins can also
promote ERK5 activation. Here we investigated the interplay between RAS-RAF-MEK-ERK and ERK5
signaling and studied the role of ERK5 in tumor cell proliferation in 2 disease-relevant cell models. We
demonstrate that although an inducible form of CRAF (CRAF:ER*) can activate ERK5 in ﬁbroblasts, the
response is delayed and reﬂects feed-forward signaling. Additionally, oncogenic KRAS and BRAF do not
activate ERK5 in epithelial cells. Although KRAS and BRAF do not couple directly to MEK5-ERK5, ERK5
signaling might still be permissive for proliferation. However, neither the selective MEK5 inhibitor
BIX02189 or ERK5 siRNA inhibited proliferation of colorectal cancer cells harbouring KRASG12C/G13D or
BRAFV600E. Furthermore, there was no additive or synergistic effect observed when BIX02189 was
combined with the MEK1/2 inhibitor Selumetinib (AZD6244), suggesting that ERK5 was neither required
for proliferation nor a driver of innate resistance to MEK1/2 inhibitors. Finally, even cancer cells with
MAPK7 ampliﬁcation were resistant to BIX02189 and ERK5 siRNA, showing that ERK5 ampliﬁcation does
not confer addiction to ERK5 for cell proliferation. Thus ERK5 signaling is unlikely to play a role in tumor
cell proliferation downstream of KRAS or BRAF or in tumor cells with ERK5 ampliﬁcation. These results
have important implications for the role of ERK5 as an anti-cancer drug target.
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Introduction
The mitogen-activated protein kinase (MAPK) signaling cas-
cades transduce extracellular signals within the cell, regulating
cytosolic and nuclear factors to inﬂuence cell fate, proliferation,
survival and motility. There are 4 MAPK kinase pathways;
extracellular-signal regulated kinase (ERK) 1/2,1 c-Jun N-termi-
nal kinase (JNK),2 p38 MAPK3 and ERK5 (also known as Big
MAP Kinase 1 (BMK1)) pathways, the latter of which is the
least well characterized.4,5 While ERK1/2 are strongly activated
by growth factors and JNK and p38 by cellular stresses, ERK5
is responsive to both growth factor and stresses. The ERK1/2
pathway comprises the small GTPase RAS, which activates the
RAF protein kinases (MKKKs), which in turn activate MEK1/2
(MAPK or ERK kinase, a MKK), which ﬁnally activates
ERK1/2 (the MAPK).6 The ERK5 pathway comprises MEKK2
and MEKK3 (the MKKKs), MEK5 (MKK) and ﬁnally ERK5
(MAPK).4,5 The ERK5 protein is encoded by the MAPK7
gene.4 It contains an N-terminal kinase domain that shares
50% identity with ERK2 and a large, unique C-terminal exten-
sion that contains a transactivation domain, nuclear localiza-
tion and export sequences and 2 proline-rich regions. Owing to
its large size, ERK5 is sometimes referred to as BMK1
(big MAPK1).5
The RAS-RAF-MEK1/2-ERK1/2 pathway is frequently de-
regulated in human cancer due to ampliﬁcation or mutation of
receptor tyrosine kinases and mutations in RAS (especially
KRAS) or BRAF (e.g. BRAFV600E).7 These mutations drive
hyperactivation of ERK1/2 which in turn promotes tumor cell
proliferation and survival. Many tumor cells become addicted
to ERK1/2 signaling providing an opportunity for tumor-selec-
tive therapeutic intervention.7 Indeed, the highly selective
BRAFV600E inhibitor vemurafenib8 is now approved for the
treatment of BRAFV600E mutant melanoma, while MEK1/2
inhibitors such as trametinib9 or selumetinib (AZD6244/
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ARRY-142886)10 are either approved or in late stage clinical
development. However, the success of such targeted
therapies has been limited by the emergence of acquired resis-
tance11,12 so there is an urgent need to identify other disease
driving pathways that can be targeted in drug combination
strategies.
Since ERK5 signaling is activated by growth factors, it is possi-
ble that it too is hyper-activated in cancer and may serve as a
drug target. Indeed, ERK5 signaling has been proposed to play a
role in receptor tyrosine kinase driven proliferation of the cervical
cancer cell line HeLa,13 the breast cancer cell lines MCF7 and
BT474,14 and the immortalised breast epithelial cell line
MCF10A.13
In contrast, the role of ERK5 downstream of RAS or RAF or in
RAS- or BRAF-dependent tumors is less clear and is subject to
conﬂicting results. Early studies indicated that oncogenic
HRASG12V could activate a co-expressed mutant form of ERK5
consisting of only the kinase domain in HEK293 cells.15 Subse-
quently HRASG12V was shown to activate ERK5 in transfected
PC12 cells but not in COS7 cells, indicating that Ras-ERK5 cou-
pling might be cell type speciﬁc,16 Crosstalk also exists between
the ERK1/2 and ERK5 pathways; MEK5D, an active form of
MEK5, co-operated with CRAF to transform NIH 3T3 cells.15
Conversely, ERK1/2 signaling can also inhibit ERK5 signaling,
since selective inhibition of ERK1/2 enhanced and sustained acti-
vation of ERK5.17,18 The relationship between ERK1/2 and ERK5
signaling is clearly complex and these studies suggest that ERK5
may lie downstream of RAS and RAF or ERK5 may be subject to
negative-feedback regulation by strong ERK1/2 activation.
Other studies implicated increased ERK5 protein levels in
tumor progression as high ERK5 expression was associated with
decreased disease-free survival in breast cancer,19,20 while in pros-
tate cancer elevated MEK5 levels correlated with the presence of
bone metastases and less favorable disease-speciﬁc survival.21
Indeed, over-expression ofMEK5 induces proliferation of the pros-
tate cancer cell line LNCaP.21 Finally, the ERK5 locus is ampliﬁed
in approximately 50% of primary hepatocellular carcinomas.22
Here we investigated the interplay between RAF-MEK1/2-
ERK1/2 signaling and the MEK5-ERK5 pathway and assessed
the role of ERK5 signaling in 2 relevant cancer cell models;
colorectal cancer cells harbouring mutant KRAS or BRAF and
cancer cells that express high levels of ERK5 due to MAPK7
ampliﬁcation. We show that in ﬁbroblasts, ERK5 can be acti-
vated downstream of an inducible CRAF:ER* construct; how-
ever, this response was delayed, resulting from ERK1/2
activation and required new protein synthesis. We ﬁnd no evi-
dence of ERK5 activation by mutant KRAS or BRAF in epithe-
lial cells, even upon overexpression and even when the ERK1/2
pathway is inhibited to remove any inhibitory cross talk. Prolif-
eration of a panel of CRC cells lines with either KRAS or BRAF
mutation was refractory to inhibition by the MEK5 inhibitor
BIX02189, and siRNA-mediated knockdown of ERK5 had no
effect on the proliferation of HCT116 cells, arguing against a
role for ERK5 in promoting tumor cell proliferation down-
stream of RAS or BRAF. Finally, the proliferation of multiple
cancer cell lines harbouring MAPK7 ampliﬁcation was insensi-
tive to BIX02189 or siRNA to ERK5, suggesting that even
ERK5 ampliﬁcation does not make a strong contribution to
tumor cell proliferation.
Results
Sustained CRAF:ER activity leads to a delayed activation of
ERK5 downstream of ERK1/2 that requires new protein
synthesis in ﬁbroblasts
To determine if activation of the RAF-MEK1/2-ERK1/2 path-
way could inﬂuence activation of ERK5 we used CR1–11 cells,
a stable clone of CCl39 ﬁbroblasts that stably express the condi-
tional kinase DCRAF:ER*.23 Treatment of these cells with
4-hydroxytamoxifen (4HT) resulted in the rapid (within
15 mins) and sustained activation of ERK1 (Fig. 1A). Interest-
ingly, ERK5 activity was also substantially increased, but its
activation was delayed by 2–3 hours compared to that of ERK1.
To determine if the delayed activation of ERK5 was dependent
upon prior ERK1/2 activation we used PD184352, an allosteric
MEK1/2-selective inhibitor.24 Although this drug can also
inhibit ERK5 signaling at doses above 10 mM, we previously
showed that at low doses it abolishes ERK1/2 signaling with no
effect on ERK5.18 Pre-treatment with 100nM PD184352 before
DCRAF:ER* activation with 4-HT prevented activation of both
ERK1 and ERK5, demonstrating that the delayed DCRAF:ER*-
driven ERK5 activation was dependent on prior activation
of ERK1/2 (Fig. 1A). Next we assessed the requirement of
ERK1/2 signaling for ERK5 activity. To do this we ﬁrst acti-
vated DCRAF:ER* with 4-HT then treated with PD184352 for
the times indicated. ERK1 activity declined immediately,
whereas ERK5 activity persisted for at least 4h before gradually
declining (Fig. 1B). Together these results demonstrate that
ERK5 can be activated as a delayed consequence of ERK1/2
activation downstream of CRAF:ER in ﬁbroblasts.
The slow increase in ERK5 activity compared with the rapid
increase in ERK1 prompted us to determine if expression of a
new protein was required for ERK5 activation. To this end
CR1–11 cells were pre-treated with the protein synthesis inhibi-
tor emetine prior to activation of CRAF:ER* with 4-HT. Activa-
tion of ERK1 proceeded normally in the presence of emetine
(Fig. 1C) whereas ERK5 activation was inhibited by up to 60%
in the presence of emetine (Fig. 1D), showing that synthesis of
new protein(s) was required for ERK5 activation. The delayed
kinetics and sensitivity to low doses of PD184352 and emetine
suggest that in CCl39 ﬁbroblasts CRAF can activate ERK5 indi-
rectly, through an ERK1/2 dependent feed forward mechanism
requiring protein neosynthesis.
Transient expression of oncogenic KRAS and BRAF does
not activate ERK5 signaling in epithelial cells
Prompted by these results we sought to investigate if ERK5
might be activated downstream of ERK1/2 activation arising
from mutant KRAS and BRAF in epithelial cells. To this end
we employed HEK293 cells and transiently transfected ERK5
and its upstream activator MEK5 (wt), together with either the
active forms of KRAS (KRASG12V) or BRAF (BRAFV600E) or the
kinase dead form of BRAF (BRAFD594A) and KRASG12V (as they
are known to co-operate with CRAF in ERK1/2 signaling25).
ERK5 activation was assessed by immuno-blotting for dual-
phosphorylation of the activation-loop (T218, Y220) and by the
reduction in mobility that is observed following kinase activa-
tion and auto-phosphorylation. Co-expression of MEK5D
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(a constitutively active form of MEK5 where the activation-loop
phosphorylation sites are mutated to aspartic acid) strongly
induced phosphorylation of the T218EY220 motif in ERK5 and
caused a decrease in ERK5 mobility (Fig. 2A). In contrast, the
oncogenic forms of KRAS and BRAF did not induce phosphor-
ylation of ERK5. KRASG12V, BRAFV600E and BRAFD549A co-
expressed with KRASG12V all induced substantial phosphoryla-
tion of endogenous ERK1/2, clearly demonstrating that these
mutants were active in HEK293 cells (Fig. 2A). As an alternative
and more sensitive measure of ERK5 activity in cells, we used a
GAL4 UAS:luciferase reporter system which is driven by the
transactivation domain of MEF2D (an ERK5 substrate that is
transcriptionally active when phosphorylated) fused to the
GAL4 DNA binding domain.26 The ERK5 MEF2D:GAL4 UAS:
luciferase reporter system was transfected into HEK293 cells
with either wild type MEK5 and the oncogenic forms of KRAS
or BRAF or MEK5D for 24h. Whereas we detected strong acti-
vation of MEF2D-mediated luciferase activity with MEK5D, we
were unable to detect any increase in luciferase activity over the
small increase observed upon expression of wild type MEK5
following co-transfection with KRASG12V, BRAFV600E or
BRAFD594A with KRASG12V (Fig. 2B). Together these results
demonstrate that oncogenic forms of BRAF and KRAS can acti-
vate ERK1/2 but cannot activate ERK5 in HEK293 cells.
Strong ERK1/2 activation by oncogenic KRAS and BRAF
does not repress activation of ERK5 in HEK293 cells
ERK1/2 signaling is known to inhibit ERK5 activation since
treatment of HeLa or CCL39 ﬁbroblasts with the MEK1/2
inhibitor PD184352 enhances MEK5-ERK5 signaling.17,18
Therefore we speculated that the lack of ERK5 activation seen
following co-expression of oncogenic KRAS or BRAF was due
to the strong activation of ERK1/2 signaling that was driving a
persistent or tonic inhibition of the ERK5 pathway. To address
this we transfected cells with oncogenic KRAS or BRAF with
MEK5 and ERK5 in the presence or absence of the highly selec-
tive allosteric MEK1/2 inhibitor selumetinib (also known as
AZD6244/ARRY-142886) to repress ERK1/2 signaling and
monitored the activation and activity of ERK5. Immuno-blot-
ting for phospho-ERK1/2 demonstrated that selumetinib
Figure 1. Sustained CRAF:ER activity leads to the delayed activation of ERK5 downstream of ERK1/2. (A) CR1-11 cells were pre-treated for 90min with 0.1mM PD184352 or
vehicle then treated with 100nM 4-HT for the times indicated. ERK1 and ERK5 were immune-precipitated and kinase activity determined as described in materials and
methods. (B) CR1-11 cells were treated with 100nM 4-HT for 6 hours prior to the addition of 0.1mM PD184352 for the times indicated. ERK1 and ERK5 activity were deter-
mined as in (A). (C) and (D) CR1-11 cells were pre-treated with 10mM emetine (Emet) for 20min prior to an 8h treatment with 100nM 4HT. ERK1 and ERK5 activity were
determined as in (A).
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inhibited the ERK1/2 phosphorylation induced by KRASG12V,
BRAFV600E or co-expression of BRAFD594A and KRASG12V.
However, even when ERK1/2 signaling was inhibited, the onco-
genic forms of KRAS and BRAF did not stimulate ERK5
phosphorylation (Fig. 2C). Furthermore, the presence of selu-
metinib failed to increase ERK5-dependent activation of the
MEF2D luciferase reporter (Fig. 2B). Thus the failure of onco-
genic KRAS and BRAF to activate ERK5 was not due to chronic
inhibition of the ERK5 pathway by ERK1/2 signaling.
MEK5-ERK5 signaling is dispensable for cell proliferation
of colorectal cancer cells
ERK5 has been proposed to play a role in the proliferation and
survival of many cancer cells lines.13,14,21,27,28 Thus, although
KRAS and BRAF failed to activate ERK5 it remained possible
that basal ERK5 signaling was permissive for proliferation in
tumor cells harbouring these oncogenes. We therefore
investigated the role of MEK5-ERK5 signaling in a panel of
CRC cells. We approached this both chemically, using the
MEK5 selective small molecule inhibitor BIX0218929 and
genetically, using siRNA mediated knock-down of ERK5. We
previously showed that BIX02189 selectively inhibits ERK5
activation in HEK293 cells and ﬁbroblasts with no effect on
ERK1/2 activity.30 We ﬁrst deﬁned the effective concentration
range for inhibition of ERK5 signaling by BIX02189 in the
CRC cell lines HCT116 (KRASG13D) and HT29 (BRAFV600E)
using the MEK5D-driven MEF2D reporter system. BIX02189
caused a dose-dependent complete inhibition of ERK5 signal-
ing with IC50 values of 0.3–1mM (Fig. 3A and 3B), as previously
reported.29 When we assayed the effect of BIX02189 on cell
proliferation we observed a substantial right shift in the dose
response curves so that inhibition of cell proliferation was only
observed at doses of 10mM or above either after 24 or 48h treat-
ment, at which ERK5 activity was inhibited by >95%; further-
more, inhibition of cell proliferation was not always complete
Figure 2. Oncogenic KRAS and BRAF do not activate ERK5 signaling when transiently expressed in HEK293 cells. (A) HEK293 cells were transfected with HA-ERK5 and
either EGFP-MEK5 wt, 5D or vector control; with either myc-BRAF wt, V600E, D594A or vector control; and with myc-KRASG12V or vector control as indicated. 24h post-
transfection cells were lysed and whole cell lysates were separated by SDS-PAGE then immunoblotted with the antibodies indicated. (B) HEK293 cell were transfected as
in (A) together with GAL4-MEF2D, GAL4:LUC and a Renilla construct. 6h post transfection cell were treated with 1mM selumetinib (sel) or vehicle control as indicated. Fol-
lowing 24h cells were then lysed and ﬁreﬂy luciferase activity was measured and normalized to Renilla. A representative experiment of 3 is shown and values are
expressed as the mean of triplicate transfections § SD (C) HEK293 cells were transfected as in (A) then 6h post transfection cell were treated with 2 mM selumetinib (sel)
or vehicle control as indicated. Following 24h cells were lysed and whole cell lysates were separated by SDS-PAGE then immunoblotted with the antibodies indicated.
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(Fig. 3A and 3B). The data suggested that doses of BIX02189
that completely inhibited ERK5 signaling had no effect on cell
proliferation. We then determined the concentrations inhibit-
ing cell proliferation by 50% (GI50) for BIX02189-dependent
inhibition of proliferation in a panel of CRC cells and consis-
tently determined a value >10mM (Fig. 3C) and yet ERK5-
MEF2D activity was completely repressed at 1–5mM in all cell
lines tested (Fig. 3D). To determine if cells grown in 3D culture,
to more closely mimic tumor conditions in vivo, were sensitive
to MEK5-ERK5 inhibition we treated HCT116 and HT29 cell
spheroids with BIX02189, drawing comparisons with selumeti-
nib. Selumetinib inhibits the proliferation of HCT116 and
HT29 cells grown in 2D31 and also inhibited the viability of
HCT116 and HT29 spheroids in a dose-dependent manner
(Fig. 4A and 4B); in contrast, HCT116 and HT29 spheroids
were insensitive to MEK5-ERK5 pathway inhibition by
BIX02189 (Fig. 4A and 4B). Finally, siRNA mediated knock-
down of ERK5 protein levels in HCT116 cells showed similar
Figure 3. Inhibition of the MEK5-ERK5 signaling pathway by BIX02189 in colorectal cancer cells does not inhibit cell proliferation. (A and B) Subconﬂuent cultures of (A)
HCT116 harbouring KRASmut or (B) HT29 harbouring BRAFmut cells were maintained in 10% FBS then treated with increasing concentrations of BIX02189 (100 nM to 30
mM) for 24 or 48 hours, and DNA synthesis was assayed by [3H]thymidine incorporation; the results are presented as an average of 3 experiments§ SD. Alternatively, cells
were transfected as in Fig. 2(C), 6h post-transfection cell were treated with increasing concentrations of BIX02189 (100 nM to 30 mM) for 24 hours. Cells were then lysed
and ﬁreﬂy luciferase activity was measured and normalized to Renilla. Results are presented as the average of 3 experiments§ SD. (C) Sub-conﬂuent cultures of colorectal
cancer cell lines harbouring KRASmut, BRAFmut or WT for both were maintained in 10% FBS and treated with increasing concentrations of BIX02189 for 24 hr. DNA syn-
thesis was assayed by [3H]-thymidine incorporation. IC50 values for each cell line are shown; the results are presented as the mean of 3 experiments § SD (D) Sub-conﬂu-
ent cultures of colorectal cancer cell lines harbouring KRASmut, BRAFmut or WT for both were transfected as in Fig. 2(C), 6h post-transfection cell were treated with
either 1 or 5 mM BIX02189. Following 24h the cells were lysed and ﬁreﬂy luciferase activity was measured and normalized to Renilla. A representative experiment of 3 is
shown and values are expressed as the mean of triplicate transfections § SD.
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results; there was no effect on cell proliferation even when
ERK5 levels were substantially knocked down (Fig. 5A and 5B).
Taken together these results demonstrate that although ERK5
activity can be completely inhibited in a number of cell lines by
BIX02189, the MEK5-ERK5 pathway is not required for prolif-
eration of CRC cells with KRAS or BRAF mutations, either in
2D or 3D culture conditions.
MEK5-ERK5 signaling does not mediate intrinsic resistance
to Selumetinib (AZD6244) in colorectal cancer cells
Intrinsic sensitivity or resistance of cancer cells that harbour
KRAS or BRAF mutations to MEK1/2 inhibitors such as selu-
metinib can be predicted, in part, by a biochemical signature;
cells with high ERK1/2 activity tend to be addicted to ERK1/2
signaling and are more responsive. In some instances intrinsic
resistance is driven by the parallel PI3-kinase signaling
pathway31; however in other instances the mechanism of
intrinsic resistance is not known. To investigate whether ERK5
signaling might compensate for ERK1/2 and be a driver of
intrinsic resistance we tested the effects of selumetinib in com-
bination with BIX02189. The CRC cell lines showed varying
sensitivities to selumetinib with respect to proliferation:
HCT116, COLO205 and HT29 being the most sensitive as
reported previously.31 As seen in Figure 3C, BIX02189 had no
effect on proliferation of any of the cell lines tested. When the
CRC cell lines were treated with the combination of selumeti-
nib and BIX02189, there were no additive or synergistic effects
observed (Fig. 6); BIX02189 could not overcome intrinsic resis-
tance to selumetinib in cells such as CaCo-2 or DLD-1. This
demonstrates that MEK5-ERK5 signaling plays no active role
in the proliferation of CRC cells, even when ERK1/2 signaling
is inhibited.
Ampliﬁcation of theMAPK7 gene does not predict a
requirement for ERK5 activity for cancer cell proliferation
An ampliﬁcation at 17p11, which contains the MAPK7 gene
(encoding ERK5 protein), is present at high frequency in hepa-
tocellular carcinoma (HCC).22 The HCC cell line SNU449 con-
tains this ampliﬁcation, and expresses high levels of ERK5
compared to BT474 cells (also known to have high ERK5
expression) (Fig. 7A). We reasoned that cells with ampliﬁcation
of ERK5 were most likely to show strong ‘ERK5 addiction’ for
proliferation. Indeed, siRNA-mediated knockdown of ERK5
has previously demonstrated a role for ERK5 in cell prolifera-
tion of SNU449 cells.22 We therefore tested the effects of
BIX02189 on the proliferation of SNU449 cells. First we con-
ﬁrmed the efﬁcacy of BIX02189 in SNU449 cells. Using the
MEK5D-driven ERK5-MEF2D:GAL4 luciferase reporter, we
demonstrated that ERK5 activity was inhibited following
BIX02189 treatment with an IC50 of 0.2mM (Fig. 7B), similar to
that observed in other cell types (Fig. 3A and 3B).29 However,
there was no effect of BIX02189 on the proliferation of
SNU449 at concentrations where ERK5 was fully inhibited
(Fig. 7B). For example, 3 mM BIX02189 abolished ERK5 signal-
ing but had no effect on SNU449 proliferation at 24 or 48 hours.
To investigate this further we tested a panel of 4 different
siRNA duplexes targeted toward ERK5 but found no effect on
SNU449 cell proliferation (Fig. 7C) even though substantial
knockdown of ERK5 protein levels was demonstrated (Fig. 7D).
Finally, we extended this study to investigate the effects of
BIX02189 on a panel of cancer cell lines that had high ERK5
protein expression (Fig. 8A). We examined the esophageal can-
cer cell line KYSE30,32 a lung cancer cell line NCI-H838 (76th
highest MAPK7 mRNA expression in the CCLE panel) and a
renal cell line A498 (very high level of ERK5 protein expression,
LG personal communication) (Fig. 8A). In these cell lines there
was no clear correlation between ERK5 protein expression and
sensitivity to BIX02189; all cell lines were comparatively refrac-
tory to treatment (Fig. 8B). In addition, the small cell lung can-
cer cell lines, NCI-H1436 and NCI-H1105, have the 6th and
7th highest MAPK7 mRNA expression in the Cancer Cell Line
Encyclopaedia (CCLE; www.broadinstitute.org/ccle), respec-
tively. However, the GI50 for BIX02189 was in excess 100mM
(data not shown). Collectively, these data suggest that high
Figure 4. Inhibition of the MEK5-ERK5 signaling pathway by BIX02189 in colorectal
cancer cell spheroids does not inhibit cell viability. (A) HCT116 harbouring KRAS-
mut or (B) HT29 harbouring BRAFmut cells were gown in 10% FBS for 96h in ultra-
low attachment plates to allow the formation of cell spheroids. The spheroids
were then treated with either selumetinib (sel) or BIX02189 at the concentrations
indicated for 72 h. Cell viability was determined using CellTitre Glo. The results are
presented as the mean of 3 experiments § the SD.
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ERK5 protein expression, including that arising from MAPK7
gene ampliﬁcation, does not drive a dependency upon ERK5
activity for cancer cell proliferation.
Discussion
There is an emerging interest in targeting therapeutics against
the ERK5 pathway in the treatment of cancer.19,28,33-39 Clinical
evidence associates high ERK5 and MEK5 levels with poor
prognosis, whereas biochemical and cell biology studies have
begun to investigate the molecular mechanisms by which the
MEK5-ERK5 pathway contributes to cell transformation
(reviewed in33,34,36). The MEK5-ERK5 pathway is proposed to
be de-regulated by oncogenes (RAS,13,40 RAF,15 COT41 and
SRC42-44) leading to an increase in activity, or by an increase in
protein level due to copy number gain of the MAPK7/ERK5
gene22; thus highlighting ERK5 as a possible drug target. In this
study we show that: (i) oncogenic KRAS and BRAF do not acti-
vate the MEK5-ERK5 pathway; (ii) cancer cells harbouring
these mutations are not sensitive to MEK5-ERK5 pathway inhi-
bition for proliferation; (iii) MEK5-ERK5 signaling does not
mediate intrinsic resistance to MEK1/2-ERK1/2 pathway inhib-
itors and ﬁnally (iv) cancer cells that over-express ERK5 are not
addicted to the MEK5-ERK5 pathway for proliferation.
We tested 3 clinically relevant oncogenic drivers of the RAS-
RAF pathway; BRAFV600E, KRASG12V and the kinase dead form
of BRAF (D594A) which cooperates with KRASG12V and
CRAF. None of these oncogenic proteins or complexes could
activate full-length ERK5 (Fig. 2). In some cell types the use of
a dominant negative form of HRAS (N17) blocks growth factor
induced ERK5 activation e.g., EGF and NGF simulated ERK5
activation in rat phaeochromocytoma PC12 cells and in mouse
myoblast C2C12 cells.16 Perhaps this is an isoform speciﬁc role
of HRAS or reﬂects the cell type speciﬁc expression of a partic-
ular adaptor or coupling protein; it will however be of interest
to conﬁrm these results with siRNA. We did ﬁnd that CRAF:
ER* could drive a feed forward activation of the ERK5 pathway
downstream of ERK1/2 in CCl39 ﬁbroblasts but this was
dependent on de novo protein expression (Fig. 1) and probably
reﬂects the ERK1/2-dependent expression of growth factors or
cytokines that then act in an autocrine manner. There is strong
precedent for ERK1/2 driving expression of growth factors and
cytokines45-47 which are biologically active and can drive activa-
tion of other pathways downstream of ERK1/2 such as PI3K.48
The proﬁle of such factors will no doubt be different in differ-
ent cell types. Therefore, it is possible that some cells such as
ﬁbroblasts (Fig. 1) may exhibit indirect RAS or RAF driven
ERK5 activation through downstream autocrine signaling,
whereas HEK293 cells clearly do not (Fig. 2). Future studies
should aim to determine the nature of this feed forward activa-
tion of ERK5 by ERK1/2.
Although we could not detect any direct or indirect activa-
tion of ERK5 by oncogenic KRAS or BRAF over-expressed in
HEK293 cells it remained possible that ERK5 could be a per-
missive signal for KRAS or BRAF-driven proliferation or could
Figure 5. siRNA mediated knockdown of ERK5 in colorectal cancer cells does not inhibit cell proliferation. (A) HCT116 cells were transfected with ERK5-speciﬁc (siERK5 1
and 2) or non-silencing (N.S.) siRNA oligos. Mock cells were left untransfected. Forty-eight hours post-transfection, DNA synthesis was assayed by [3H]thymidine incorpo-
ration; the results are presented as an average of 3 experiments§ SD (B) HCT116 cells were transfected as in (A) ERK5 and ERK1 abundances were determined by Western
blot analysis of whole-cell extracts.
Figure 6. Inhibitors of ERK1/2 and ERK5 signaling do not synergise to inhibit colo-
rectal cancer cell proliferation. Sub-conﬂuent cultures of colorectal cancer cell lines
harbouring KRASmut, BRAFmut or WT for both were maintained in 10% FBS and
treated with 2 mM selumetinib (sel) and/or 1 mM BIX02189 for 24 hr. DNA synthe-
sis was assayed by [3H]-thymidine incorporation; the results are presented as the
mean of 3 experiments§ SD.
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be a driver of innate resistance to MEK1/2 inhibitors. For
example, Mulloy et al49 demonstrated that expression of the G1
cyclin, CCND1, was stimulated by the MEK5-ERK5 pathway
independently of the MEK1/2-ERK1/2 pathway. Since expres-
sion of CCND1 can confer resistance to ERK1/2 pathway
inhibitors50 this might be a plausible role for ERK5 signaling. It
is also consistent with the observation that constitutively active
MEK5 can drive the proliferation of HEK293 and LNCaP
cells.21 However, in colon cancer cells harbouring KRAS or
BRAF mutations chemical or genetic inhibition of the MEK5-
ERK5 pathway did not inhibit proliferation (Figs. 3, 4 and 5)
demonstrating that this pathway was not important for prolif-
eration in these tumor cells. MEK1/2-ERK1/2 signaling is
known to inhibit ERK5 signaling in some cells,17,18 thus it was
possible that treatment of KRAS- or BRAF-driven tumor cells
with MEK1/2 inhibitors might activate the MEK5-ERK5
pathway and reveal a dependency on this pathway for cell pro-
liferation. Indeed, not all KRAS and BRAF driven tumor cells
undergo cell cycle inhibition upon MEK1/2 inhibitor treat-
ment.31 However, we did not observe ERK5 activation in tran-
sient transfection experiments with oncogenic KRAS or BRAF
when we inhibited the canonical ERK1/2 pathway (Fig. 2) and
there were no synergistic or additive effects of combining selu-
metinib with BIX02189 to inhibit both MEK1/2 and MEK5 in
selumetinib-resistant KRAS- or BRAF-driven colorectal cancer
cell lines (Fig. 6).
Finally, many driving oncogenes are overexpressed as a
result of gene ampliﬁcations e.g. the receptor tyrosine kinase
EGFR.51 Cancer cells become addicted to the ampliﬁed onco-
protein and this provides a therapeutic window in which
the cancer cells are hypersensitive to inhibition of the elevated
protein. MAPK7, the gene encoding ERK5, is ampliﬁed in
Figure 7. The hetatocellular carcinoma cell line SNU449 expresses high levels of ERK5 but is not dependent on MEK5-ERK5 signaling for proliferation. (A) Subconﬂuent
cultures of BT474 and the liver hepatocellular carcinoma cell line SNU449 harbouring an ampliﬁcation containing the ERK5 gene were maintained in 10% FBS. Cells were
lysed, whole cell lysates were separated by SDS-PAGE and immunoblotted with the antibodies indicated. (B) Subconﬂuent cultures of SNU449 cells were maintained in
10% FBS then treated with increasing concentrations of BIX02189 (100 nM to 30 mM) for 24 or 48 hours, and DNA synthesis was assayed by [3H]thymidine incorporation;
the results are presented as an average of 3 experiments § SD. Alternatively, cells were transfected as in Fig. 2(C), 6h post-transfection cell were treated with increasing
concentrations of BIX02189 (100 nM to 30 mM) for 24 hours. Cells were then lysed and ﬁreﬂy luciferase activity was measured and normalized to Renilla. A representative
experiment of 3 is shown and values are expressed as the mean of triplicate transfections § SD (C) SNU449 cells were transfected with ERK5-speciﬁc as indicated or non-
silencing (control) siRNA oligos. Mock cells were left untransfected. Seventy-two hours post-transfection, ERK5 and a-tubulin abundances were determined by Western
blot analysis of whole-cell extracts. (D) SNU449 cells were transfected as in (C) cell viability was determined by MTT assay. A representative experiment of 2 is shown and
values are expressed as the mean of 8 values § CoV.
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approximately 50% of hepatocellular carcinomas.22 Neverthe-
less, inhibition of the MEK5-ERK5 pathway either chemically
or genetically in SNU449 cells – a hepatocellular cancer cell
line with an ERK5 ampliﬁcation – or in a panel of cancer cell
lines with MAPK7 copy number gain and elevated ERK5 pro-
tein levels did not reduce cell proliferation (Figs. 7 and 8) sug-
gesting that even high levels of ERK5 do not confer ERK5
addiction for tumor cell proliferation.
Notably our results contrast the strong anti-proliferative
effects observed in triple negative breast cancer cells treated
with TG02, a clinical stage inhibitor which targets ERK5.19
However, TG02 is 10-fold more potent against CDK1, CDK2,
CDK3, CDK5 and CDK9 than ERK552 and this likely accounts
for the inhibition of proliferation in these studies; indeed, the
mixed arrest of cells in G1 and G2 is consistent with CDK1,
CDK2 and CDK9 inhibition. Taken together, our results argue
that the role of the MEK5-ERK5 pathway in tumor develop-
ment is not through driving tumor cell proliferation and sug-
gests that anti-tumor effects seen with ERK5 pathway targeted
therapies28 are likely through other mechanisms. Given the
strength of the clinical evidence suggesting a role for MEK5
and ERK5 in cancer development,20-22 it will be of great interest
to investigate the role of this pathway in other aspects of tumor
cell biology.
Materials and methods
Materials
Cell culture reagents were purchased from Invitrogen and
Sigma. Selumetinib (AZD6244; ARRY142886) was supplied by
P. Smith, AstraZeneca, Cambridge, UK. An initial small quan-
tity of BIX02189 was kindly provided by R. Snow, Boehringer-
Ingelheim and used to conﬁrm efﬁcacy, potency and selectivity;
subsequently a stock was prepared by Dr Jonathan Clark, Bab-
raham Biological Chemistry Facility for this study. PD184352
was from Selleck. Mouse anti-HA was provided by the Babra-
ham Institute Monoclonal facility. Phospho-ERK5 TEY (3371,
http://www.cellsignal.com/products/primary-antibodies/3371),
myc 9B11 (2276, http://www.cellsignal.com/products/primary-
antibodies/2276) and phospho-ERK1/2 (9106, http://www.cell
signal.com/products/primary-antibodies/9106) antibodies were
from Cell Signaling Technology. Total ERK5 antibodies were
from Santa Cruz (sc1284, Figures 2, 4 and 6, http://www.scbt.
com/datasheet-1284-erk-5-c-20-antibody.html) and Cell Sig-
naling Technology (3372S, Figure 7, http://www.cellsignal.com/
products/primary-antibodies/3372?hit=productId &NtteD3372S). A
total Raf-B antibody (sc-5284, http://www.scbt.com/datasheet-
5284-raf-b-f-7-antibody.html) and tubulin (sc-8035, http://
www.scbt.com/datasheet-8035-a-tubulin-tu-02-antibody.
html) were obtained from Santa Cruz and total MEK5 anti-
body (AB3184, http://www.merckmillipore.com/GB/en/prod
uct/Anti-MEK5-Antibody,MM_NF-AB3184) from Chemicon.
Total ERK1 antibody was from BD Biosciences (610031,
http://www.bdbiosciences.com/ds/pm/tds/610031.pdf). Antibodies
for actin were from Sigma (A4700, http://www.sigmaaldrich.com/
catalog/product/sigma/a4700?langDenandregionDGB). SRB and
XTTwere purchased fromRoche. CellTitre-Glo 3DCell Viability
Assay was purchased from Promega (https://www.promega.co.uk/
products/cell-health-and-metabolism/cell-viability-assays/celltiter_
glo-3d-cell-viability-assay/). Emetine (http://www.sigmaaldrich.
com/catalog/product/sigma/e2375?langDen andregionDGB) and
4HT (http://www.sigmaaldrich.com/catalog/product/sial/t176?langD
en andregionDGB) purchased from Sigma.
Cell culture
CR1-11 cells are a stable clone of CCl39 ﬁbroblasts expressing
the conditional kinase ΔCRAF:ER*. Culture of CR1-11,
HEK293, SW48, CaCo2, HCT116, DLD-1, COLO205, HT29
and CO115 cells has been described previously.23,26,31 BT474
were a kind gift from C. Watson, University of Cambridge and
were cultured as described.20 Hela, A-498, SNU449, NCI-H838,
NCI-H1105, and NCI-H1436 cells were obtained from ATCC
(Rockvill, MD). HeLa, A-498, SNU449 and NCI-H838 cells
were maintained in RPMI-1640 medium supplemented with
10% FBS and NCI-H1105 and NCI-H1436 cells in DMEM-
Ham’s F12 medium with 5% FBS. KYSE30 cells were purchased
Figure 8. Tumor cell sensitivity to the MEK5-ERK pathway inhibitor BIX02189 does not correlate with ERK5 protein expression. (A) Relative ERK5 protein expression in a
panel of tumor cell lines determined by immuno-blot analysis of whole-cell extracts. (B) GI50 data generated with BIX02189 in adherent tumor cells lines following 72 h
of incubation. Data represent the mean § SD of three independent experiments.
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from DSMZ (Germany) and maintained in DMEM Ham’s F12
medium supplemented with 10% FBS. All cell lines were cul-
tured at 37oC in an atmosphere of 5% CO2 and 95% humidity.
HCT116 and HT29 cell spheroids
HCT116 and HT29 cells were cultured in round bottom, ultra-
low attachment 96-well plate tissue culture plates (http://www.
sigmaaldrich.com/catalog/product/sigma/cls4520?langD
enandregionDGB) in 200 ml culture medium (described above)
using the method described by Vinci et al.53
Plasmids
The HA-ERK5 and EGFP-MEKwt and 5D constructs have
been described previously26 and were derived from constructs
provided by J.D. Lee. Myc-BRAF constructs were a kind gift
from R. Marais, Cancer Research UK Manchester Institute,
Manchester. Myc-KRASG12V construct was from A. Cox
UNC, Chapel Hill, North Carolina. GAL4-MEF2D was a
kind gift from J.C.McDermott, Center for Research in Biomo-
lecular Interactions, York University, Toronto, Canada;
GAL4:LUC reporter from D. Gillespie, University of Glasgow,
Glasgow, UK.
Immune complex kinase assays
Following stimulation, as described, active kinase complexes
were immunoprecipitated from cell extracts normalized for
protein content. The extracts were mixed, for 3 h at 4C,
with a 10 ml bed volume of Protein A–Sepharose (ERK1)
(Sigma, http://www.sigmaaldrich.com/catalog/product/sigma/
p9424?lang=en andregion=GB) or Protein G–Sepharose
(ERK5) (GE Healthcare, http://www.gelifesciences.com/
webapp/wcs/stores/servlet/ProductDisplay?categoryIdD11504
andcatalogId=10101 andproductId=21386 andstoreId=12751
andlangIdD¡1) and antibody; 5 ml of rabbit anti-ERK1 anti-
body (BD Biosciences, http://www.bdbiosciences.com/eu/appli
cations/research/stem-cell-research/stem-cell-signaling/
human/puriﬁed-mouse-anti-erk1-mk12/p/610031), or 10ml of
goat anti-ERK5 antibody (Santa Cruz Biotechnology, http://
www.scbt.com/datasheet-1284-erk-5-c-20-antibody.html). The
bead complexes were washed twice with lysis buffer and once
in kinase buffer (30 mM Tris, pH 8, 20 mM MgCl2, 2 mM
MnCl2, 25 mM b-glycerol phosphate and 0.1 mM sodium van-
adate). Kinase activities were assessed by incubating the
drained beads in 30 ml of kinase buffer supplemented with
10 mM ATP, 3 mCi of [g-32P]ATP and either 7 mg of myelin
basic protein (ERK1 assays), or 8 mg of glutathione S-transfer-
ase (GST)-MEF2C (175–327) (ERK5 assays) for 30 min at
30 C in a shaking incubator. Kinase reactions were terminated
by boiling samples in 4xLaemmli SDS sample buffer before
resolving by SDS-PAGE. Gels were ﬁxed and dried and incor-
poration of 32P into respective substrates quantiﬁed by Phos-
phorimager (Fuji). Unless otherwise indicated, data are either
combined from independent experiments or are from a single
experiment on triplicate dishes, representative of at least 2
others giving similar results.
Luciferase assays
HEK293, SW48, CaCo2, HCT116, DLD-1, COLO205 and
CO115 cells were transfected using Lipofectamine 2000 (Life
Technologies, https://www.lifetechnologies.com/uk/en/home/
brands/product-brand/lipofectamine/lipofectamine-2000.html
), according to the manufacturer’s instructions. HT29 and
SNU449 cells were transfected using JetPEI (PolyPlus, http://
www.polyplus-transfection.com/2009/08/high-throughput-
screening-jetpei/) according to the manufacturer’s instructions.
BIX02189 was added at concentrations indicated, 6–h post
transfection. After a further 16–18–h cells were harvested and
processed for ﬁreﬂy and renilla luciferase activity using the
Dual Luciferase Reporter (Promega, http://www.promega.co.
uk/products/reporter-assays-and-transfection/reporter-assays/
dual_luciferase-reporter-assay-system/) assay according to the
manufacturer’s instructions.
Western blot analysis
For western blotting 6 cm dishes were routinely transfected as
described or 10 cm dishes were routinely used to prepare whole
cell extracts of cancer cell lines. Cells were treated BIX02189 or
Selumetinib at the concentrations and for the indicated times
prior to harvesting and western blotted as previously
described.54,55
Assay of cell proliferation
Cell proliferation were measured by [3H]thymidine incorpo-
ration and were performed as described previously.31 To deter-
mine the sensitivity of additional tumor cell lines with high
ERK5 expression to ERK5 kinase inhibition, the effect of
continuous treatment over a 72 h period was ascertained
using either a Sulforhodamine B (SRB) assay for adherent
lines or XTT assay for non-adherent lines, as previously
described.42,56,57 Spheroid cell viability was measured using
CellTitre-Glo 3D Cell Viability Assay reagent as previously
described.53
siRNA sequences and RNAi
For transient RNAi, the following oligos were used: siERK5 1,
GACCCACCUUUCAGCCUUA; siERK5 2, GGAUGGC-
CAGGCAGAUUCA; and siN.S. (non-silencing) as described
by Roberts et al58; ERK5 Euro, GGUGUUGGCUUUGACCUG-
GAGGAAU; ERK5 Dharma 2 (J-003513–09); ERK5 Dharma 3
(J-003513-08); Dharma control 1 (D-001810-01-20) from
Dharmacon; control stealth (46-2002) from Invitrogen. For
HCT116 cell transfection 100pmol of the appropriate oligo was
mixed with 1ml opti-MEM and 10ml lipofectamine2000, and
then incubated at room temperature for 20 min. 5 ml of 2 £
105 cells/ml in penicillin/steptamycin free media were then
added and mixed well. 6 h post transfection the media was
changed to normal media and the cell incubated overnight. The
following day the cells were trypsinised and counted and plated
in the appropriate vessel. For SNU449 2£105 cells were seeded
per well of a 6 well plate 24h prior transfection. siRNA was
added to 1.25 ml opti-MEM to give a ﬁnal concentration of
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10nM, and 25ml of lipofectamine2000 was added to 1.25 ml
opti-MEM, these were then mixed and incubated at room tem-
perature for 20min. 510 ml aliquots of mix were added/ well
and the media replaced after 6h. The following day the
cells split into 96 well plates containing 3 £ 103 cells/ well
and the remaining cells were seeded into 6 cm plates for
immunoblotting.
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